기관지천식에서 CpG 투여가 알레르기 염증에 미치는 효과

참고문헌 (11)

1. Barnes PJ, "The costs asthma", Eur Respir J, 9, pp.636~642 (1996)
2. Chung KF, "Difficult", therapy-resistant asthma: the need for an integrated approach to define clinical phenotypes, evaluatte risk factors, understand pathophysiology and final novel therapies, 1999, pp.13, 1198~1208
3. Adcock IM, "New targets for drug development in asthma", Lancet, 372, pp.1073~1087 (2008)
4. Crameri R, "Novel vaccines and adjuvants for allergen-specific immunotherapy", Curr Opin Immunol, 18, pp.761~768 (2006)
5. Fonseca DE, "Use of CpG oligonucleotides in treatment of asthma and allergic disease", Adv Drug Deiv Rev, 61, pp.256~262 (2009)
6. Jarnicki AG, "A.G. Attenuating regulatory T cell induction by TLR agonists through inhibition of p38 MAPK signaling in dendritic cells enhances their efficacy as vaccine adjuvants and cancer immunotherapeutics", J Immunol, 180, pp.3797~3806 (2008)
7. Shirota H, "Regulation of murine airway esinophilia and Th2 cells by antigen-conjugated CpG oligodeoxynucleotides as a novel antigen-specific immunomodulator", J Immunol, 164, pp.5575~5582 (2000)
8. Cho JY, "Immunostimulatory DNA inhibits transforming growth factor-beta expression and airway remodeling", Am J Respir Cell Mol Biol, 30, pp.651~661 (2004)
9. Reinero CR, "Adjuvanted rush immunotherapy using CpG oligodeoxynucleotides in experimental feline allergic asthma", Vet Immunol Immunopathol, 121, pp.241~250 (2008)
10. 손정호, "바퀴항원 천식모델에서 기도내 바퀴항원과 CpG 병용 투여가 바퀴항원에 의한 알레르기 염증에 미치는 효과", 천식 및 알레르기, 29(3), pp.194~199 (2009), 대한천식알레르기학회
11. Krieg AM, "Therapeutic potential of Toll-like receptor 9 activation", Nat Rev Drug Discov, 5, pp.471~484 (2006)

관련 논문AI추천